BWV BLUE WATER VACCINES INC

Blue Water Biotech Announces It Has Regained Compliance with Nasdaq Listing Rule 5250(c)(1)

Blue Water Biotech Announces It Has Regained Compliance with Nasdaq Listing Rule 5250(c)(1)

CINCINNATI, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (Nasdaq: BWV) ("BWB" or the “Company”) today announced that it has received a letter from the Nasdaq Stock Market, LLC ("Nasdaq") stating that the Company has regained compliance with the Nasdaq Stock Market, LLC Listing Rule 5250(c)(1) (the "Rule").

The Rule requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (SEC). On October 20, 2023, BWB filed its Form 10-Q for the period ended June 30, 2023, and thus is now current on its SEC financial reporting obligations.

About Blue Water Biotech, Inc.

Blue Water Biotech, Inc. is a commercial stage biotechnology company focused on the research, development, and commercialization of innovative solutions for oncology. The Company currently has Entadfi®, an oral therapeutic for the treatment of benign prostatic hyperplasia (BPH), a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.

Investor and Media Contact Information:

Russo Partners, LLC

Nic Johnson and Harrison Seidner, PhD

Telephone: (212) 845-4242

Email:



EN
01/11/2023

Underlying

BWVBLUE WATER VACCINES INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BLUE WATER VACCINES INC

 PRESS RELEASE
Free
BWV BLUE WATER VACC...

Onconetix Announces Appointment of Seasoned Biotech Executives Dr. Aji...

Onconetix Announces Appointment of Seasoned Biotech Executives Dr. Ajit Singh and Dr. Thomas Meier to Its Board of Directors CINCINNATI, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Onconetix, Inc., (Nasdaq: ONCO) ("Onconetix" or the “Company”), a commercial stage biotechnology company focused on developing and commercializing therapeutics, diagnostics, and services for clinicians and patients in oncology, today announced the appointment of Ajit Singh, Ph.D. and Thomas Meier, Ph.D. to its Board of Directors. “We are thrilled to announce the addition of Dr. Singh and Dr. Meier to the Board of Direct...

February 13, 2024 1 EN
 PRESS RELEASE
Free
BWV BLUE WATER VACC...

Onconetix™ Chief Executive Officer Dr. Neil J. Campbell Issues Letter ...

Onconetix™ Chief Executive Officer Dr. Neil J. Campbell Issues Letter to Shareholders CINCINNATI, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Onconetix, Inc., (Nasdaq: BWV) ("Onconetix" or the “Company”) today issued the following shareholder letter from the Company’s Chief Executive Officer, Dr. Neil Campbell. To Our Valued Shareholders, As 2023 draws to a close, I am eager to share with you the significant strides Onconetix, Inc. (formerly Blue Water Biotech, Inc.) has made in our journey towards becoming a leader in oncology. This past quarter has been transformative, marked by strategic shif...

December 19, 2023 1 EN
 PRESS RELEASE
Free
BWV BLUE WATER VACC...

Blue Water Biotech Acquires Proteomedix as Part of Transformation to C...

Blue Water Biotech Acquires Proteomedix as Part of Transformation to Commercial Stage Oncology Company; Announces Name Change to Onconetix™ Transaction strengthens commercial business with addition of diagnostics product and initial focus on prostate cancer CINCINNATI, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (Nasdaq: BWV) ("BWB" or the “Company”) today announced the acquisition of Proteomedix AG, a private, commercial-stage diagnostics oncology company (the “Transaction”), and introduced a new name for the combined Company: Onconetix, Inc. The Transaction reflects a t...

December 18, 2023 1 EN
 PRESS RELEASE
Free
BWV BLUE WATER VACC...

Blue Water Biotech Signs Non-Binding Term Sheet to Acquire a Commercia...

Blue Water Biotech Signs Non-Binding Term Sheet to Acquire a Commercial Stage Oncology Company Transaction will Advance Company’s Shift in Business Strategy Aligned with Life Sciences Industry Expertise of New Leadership Team CINCINNATI, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (Nasdaq: BWV) ("BWB" or the “Company”), today announced the execution of a non-binding term sheet regarding the acquisition of a private commercial stage oncology biotechnology company (the “Proposed Transaction”). This latest announcement is part of the Company’s new business strategy focusing ...

November 2, 2023 1 EN
 PRESS RELEASE
Free
BWV BLUE WATER VACC...

Blue Water Biotech Announces It Has Regained Compliance with Nasdaq Li...

Blue Water Biotech Announces It Has Regained Compliance with Nasdaq Listing Rule 5250(c)(1) CINCINNATI, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (Nasdaq: BWV) ("BWB" or the “Company”) today announced that it has received a letter from the Nasdaq Stock Market, LLC ("Nasdaq") stating that the Company has regained compliance with the Nasdaq Stock Market, LLC Listing Rule 5250(c)(1) (the "Rule"). The Rule requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (SEC). On October 20, 2023, BWB filed its Form...

November 1, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch